Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Patent metadata

Field	Value
Publication number	US-9957486-B2
Application number	US-201414766620-A
Country	US
Kind code	B2
Filing date	Feb 7, 2014
Priority date	Feb 8, 2013
Publication date	May 1, 2018
Grant date	May 1, 2018

Abstract

Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.

First claim

What is claimed:

1. A recombinant polynucleotide encoding a respiratory syncytial virus (RSV), wherein the nucleotide sequence encoding the RSV L protein comprises a sequence that is codon pair deoptimized from the corresponding sequence of a parent virus and the codon-pair deoptimization results in the nucleotide sequence encoding the RSV L protein being from about 70% to about 90% identical to the corresponding sequence of SEQ ID NO:1.

2. The recombinant polynucleotide of claim 1 , wherein the nucleotide sequence encoding the RSV L protein is about 79% identical to the corresponding sequence of SEQ ID NO:1.

3. The recombinant polynucleotide of claim 2 , wherein the codon pair deoptimized nucleotide sequence encoding the RSV L protein has the sequence of nucleotides 8387 to 14884 of SEQ ID NO: 5.

4. The recombinant polynucleotide of claim 1 , further comprising a nucleotide change in one or more of the following:
a. a change in the codon encoding amino acid 136 of the N protein,
b. a change in the codon encoding amino acid 114 of the P protein,
c. a change in the codon encoding amino acid 88 of the M2-1 protein, or
d. a change in the codon encoding amino acid 73 of the M2-1 protein.

5. The recombinant polynucleotide of claim 4 , wherein any one of said nucleotide changes causes an amino acid other than:
a. lysine to be encoded at position 136 of the N protein,
b. glutamic acid to be encoded at position 114 of the P protein,
c. asparagine to be encoded at position 88 of the M2-1 protein, or
d. alanine to be encoded at position 73 of the M2-1 protein.

6. The recombinant polynucleotide of claim 5 , wherein arginine is encoded at position 136 of the N protein, valine is encoded at position 114 of the P protein, lysine is encoded at position 88 of the M2-1 protein, and/or serine is encoded at position 73 of the M2-1 protein.

7. A method of producing a recombinant RSV, comprising expressing the polynucleotide of claim 1 in a cell.

8. A method of producing an immune response to a viral protein, comprising administering the recombinant RSV of claim 7 to an animal.

9. The method of claim 8 , wherein the animal is a mammal.

10. The method of claim 9 , wherein the mammal is a human.

11. The recombinant polynucleotide of claim 1 comprising SEQ ID NO:4.

12. The recombinant polynucleotide of claim 1 comprising SEQ ID NO:5.

Assignees

• Us Health
• Univ New York State Res Found
• Us Health

Inventors

• Collins Peter L
• Le Nouën Cyril
• Brock Linda G
• Buchholz Ursula J
• Dinapoli Joshua Marc
• Mueller Steffen
• Wimmer Eckard

Classifications

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2760/00034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18562

  by genetic engineering · CPC title

• C12N2760/18522

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title